Literature DB >> 8756346

A novel mesoderm inducer, Madr2, functions in the activin signal transduction pathway.

J C Baker1, R M Harland.   

Abstract

A functional assay to clone mouse mesoderm inducers has identified the mouse gene Mad related 2 (Madr2). Madr2 induces dorsal mesoderm from Xenopus ectoderm and can mimic the organizer in recruiting neighboring cells into a second axis. By analyzing the expression of a lacZ/Madr2 fusion protein, we find Madr2 confined to the nucleus in the deep, anterior cells of the second axis, whereas in epidermal and more posterior cells the protein is cytoplasmically localized. This context-dependent nuclear localization suggests that in certain regions of the embryo, Madr2 responds to a localized signal and amplifies this signal to form the second axis. Furthermore, although Madr2 remains unlocalized in ectodermal explants, addition of activin enhances the concentration of Madr2 in the nucleus. Significantly, a functional lacZ fusion to a carboxy-terminal portion of Madr2 is nuclear localized even in the absence of activin. This indicates that Madr2 contains a domain that can activate downstream components and a repressive domain that anchors the protein in the cytoplasm. Nuclear localization of Madr2 in response to activin, and the activin-like phenotypes induced by overexpression of Madr2, indicate that Madr2 is a signal transduction component that mediates the activity of activin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8756346     DOI: 10.1101/gad.10.15.1880

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  55 in total

1.  Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase.

Authors:  Y Zhang; C Chang; D J Gehling; A Hemmati-Brivanlou; R Derynck
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

2.  A distinct nuclear localization signal in the N terminus of Smad 3 determines its ligand-induced nuclear translocation.

Authors:  Z Xiao; X Liu; Y I Henis; H F Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

3.  Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins.

Authors:  M Fukuchi; T Imamura; T Chiba; T Ebisawa; M Kawabata; K Tanaka; K Miyazono
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

Review 4.  Specificity in transforming growth factor-beta signaling pathways.

Authors:  C J Ring; K W Cho
Journal:  Am J Hum Genet       Date:  1999-03       Impact factor: 11.025

5.  High-throughput functional screen of mouse gastrula cDNA libraries reveals new components of endoderm and mesoderm specification.

Authors:  Eric Chiao; Jeff Leonard; Kari Dickinson; Julie C Baker
Journal:  Genome Res       Date:  2005-01       Impact factor: 9.043

6.  TGF-beta-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein.

Authors:  X Shen; P P Hu; N T Liberati; M B Datto; J P Frederick; X F Wang
Journal:  Mol Biol Cell       Date:  1998-12       Impact factor: 4.138

7.  Determinants of specificity in TGF-beta signal transduction.

Authors:  Y G Chen; A Hata; R S Lo; D Wotton; Y Shi; N Pavletich; J Massagué
Journal:  Genes Dev       Date:  1998-07-15       Impact factor: 11.361

8.  Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors.

Authors:  M Kawabata; H Inoue; A Hanyu; T Imamura; K Miyazono
Journal:  EMBO J       Date:  1998-07-15       Impact factor: 11.598

9.  Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein.

Authors:  J M Yingling; M B Datto; C Wong; J P Frederick; N T Liberati; X F Wang
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

10.  Neotendon formation induced by manipulation of the Smad8 signalling pathway in mesenchymal stem cells.

Authors:  Andrea Hoffmann; Gadi Pelled; Gadi Turgeman; Peter Eberle; Yoram Zilberman; Hadassah Shinar; Keren Keinan-Adamsky; Andreas Winkel; Sandra Shahab; Gil Navon; Gerhard Gross; Dan Gazit
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.